Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Magdalena Megova"'
Autor:
Ondrej Kalita, Zuzana Sporikova, Marian Hajduch, Magdalena Megova Houdova, Rastislav Slavkovsky, Lumir Hrabalek, Matej Halaj, Yvona Klementova, Martin Dolezel, Jiri Drabek, Lucie Tuckova, Jiri Ehrmann, Jana Vrbkova, Radek Trojanec, Miroslav Vaverka
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1280-1293 (2021)
This prospective population-based study on a group of 132 resected IDH-wildtype (IDH-wt) glioblastoma (GBM) patients assesses the prognostic and predictive value of selected genetic biomarkers and clinical factors for GBM as well as the dependence of
Externí odkaz:
https://doaj.org/article/f026a67f57ad4e82bce2e57e883a6eb6
Autor:
Jana Vrbkova, Ondrej Kalita, Marian Hajduch, Zuzana Sporikova, Matej Halaj, Lumir Hrabalek, Martin Dolezel, Jiri Ehrmann, Yvona Klementova, Miroslav Vaverka, Magdalena Megova Houdova, Jiri Drabek, Radek Trojanec, Rastislav Slavkovsky, Lucie Tučková
Publikováno v:
Current Oncology, Vol 28, Iss 122, Pp 1280-1293 (2021)
Current Oncology
Volume 28
Issue 2
Pages 122-1293
Current Oncology
Volume 28
Issue 2
Pages 122-1293
This prospective population-based study on a group of 132 resected IDH-wildtype (IDH-wt) glioblastoma (GBM) patients assesses the prognostic and predictive value of selected genetic biomarkers and clinical factors for GBM as well as the dependence of
Autor:
Zuzana Sporikova, Rastislav Slavkovsky, Lucie Tuckova, Ondrej Kalita, Magdalena Megova Houdova, Jiri Ehrmann, Marian Hajduch, Lumir Hrabalek, Miroslav Vaverka
Publikováno v:
Applied Immunohistochemistry and Molecular Morphology
Patients below 55 years were genetically studied because the prevalence of isocitrate dehydrogenase 1 (IDH1) decreases in older patients and on grounds of cost-effectiveness, as suggested by the World Health Organization (WHO) in 2016. The aim of our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c609aad2608b28a2f354f392d37718e3
http://publikace.k.utb.cz/handle/10563/1010749
http://publikace.k.utb.cz/handle/10563/1010749
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Magdalena Megova, Jana Dvorackova, Magdalena Uvírová, Jiri Drabek, Jarmila Simova, Marian Hajduch, Irena Urbanovska, Petr Buzrla, Tomáš Paleček, Zachary Dwight, Ondrej Kalita, Lucie Tučková
Publikováno v:
Pathology Oncology Research
Mutations in IDH1/2 genes are a marker of good prognosis for glioma patients, associated with low grade gliomas and secondary glioblastomas. Immunohistochemistry and Sanger sequencing are current standards for IDH1/2 genotyping while many other metho
Autor:
Jana Vrbkova, Radek Trojanec, Miloslava Zlevorová, Miroslav Vaverka, O. Kalita, Marian Hajduch, Magdalena Megova, Lumir Hrabalek, Jiri Drabek, Lucie Tučková
Publikováno v:
Clinical Neurology and Neurosurgery. 144:39-43
Objectives Significant progress in treatment strategies improves the expectations of patients with extracranial cancers. Metastases are the primary consideration in patients with cancer history. In the case of neurologic disorders, the patient should
Publikováno v:
Onkologie. 10:196-198
Extraventrikularni, supratentorialni ependymomy jsou velmi vzacne nadory dospělých. Z toho důvodu faktory, ktere ovlivňuji prognozu, jsou znamy jen omezeně. Předkladame kazuistiky dvou pacientů, kteři byli vysetřovani pro prvni epileptický
Autor:
Jan Bouchal, Katerina Bouchalova, Gvantsa Kharaishvili, Jana Vrbkova, Magdalena Megova, Alice Hlobilkova
Publikováno v:
ResearcherID
Background: Breast cancer (BC), the most frequent malignancy in women worldwide, is currently diagnosed in about 1.4 million female patients annually. Approximately 10-20% of BC is represented by triple negative breast cancer (TNBC) which is aggressi
Autor:
Magdalena Megova, Ondrej Kalita, Radek Trojanec, Vladimira Koudelakova, Jiri Drabek, Marian Hajduch
Publikováno v:
Journal of Neuroscience Research. 92:1611-1620
Over the past few years, new biomarkers have allowed a deeper insight into gliomagenesis and facilitated the identification of possible targets for glioma therapy. Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations have been shown to be promising bi
Autor:
Miroslav Vaverka, Magdalena Megova, Radek Trojanec, Lucie Tučková, O. Kalita, Miloslava Zlevorová
Publikováno v:
Europe PubMed Central
Background Gliosarcoma is a rare, malignant CNS tumor with a very poor prognosis. Gliosarcoma is a variant of glioblastoma multiforme, which is characterized by the presence of both glial and mesenchymal components. The treatment strategy for gliosar